Wortmannin as Targeted Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
Purpose: To investigate the inhibitory effect of wortmannin on inhibition of BT-20 and BT-474 breast cancer cells in Athymic nu/nu mice model.
Methods: Forty Athymic nu/nu mice were randomly assigned to 4 groups of 10 each, namely, BT-20 control, BT-20 treatment, BT-474 control and BT-474 treatment groups. The mice were injected with 2.5 x 105 BT-20 and BT-474 cells under anesthesia. Those in the treatment groups were given wortmannin (7 mg/kg) in DMSO daily intraperitoneally whereas the animals in control groups received an equal volume of DMSO for 21 days after the cancer attained palpable stage. Western blot analysis was carried out using enhanced chemiluminescence reagent while Protean IEF cell unit was used for 1-D electrophoresis.
Results: The results showed a significant decrease in the growth of the tested cancer cell lines on treatment with wortmannin at 7 mg/kg daily for 21 days. The volume of tumor in the treatment group was reduced to 42.72 ± 9.45 compared to 79.43 ± 17.11 mm3 in the control group after 21 days treatment (p < 0.005). It also changed the expression of microRNA in BT-20 cells. Exposure of BT-20 cells to wortmannin for 24 h resulted in the altered expression of proteomes. Wortmannin treatment increased the expression of miRs including miR 19a/b, 22, 29b/c, 181c/d, 195 and 663. Western blot data showed increase in the expression of NME1 (NM23 H1) and reduction in the expression of vimentin after treatment with wortmannin.
Conclusion: Wortmannin can be of benefit in the treatment of human breast cancer.
Keywords: Wortmannin, Vimentin, Tumor growth, Expression of microRNA, Proteomes
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.